This pattern may suggest that brexpiprazole’s partial agonism at dopamine D2 receptors not only mitigates hyperprolactinemia but may also potentially support global functioning in patients transitioning from potent antagonists. This evidence concerns the gene DRD2 and hyperprolactinemia.